Literature DB >> 21128775

Ocular melanoma.

Nora V Laver1, Margaret E McLaughlin, Jay S Duker.   

Abstract

CONTEXT: Intraocular melanoma of the ciliary body and choroid is the most common primary ocular malignant tumor in adults and the most common noncutaneous melanoma.
OBJECTIVE: To describe the most salient clinical features, histopathologic findings, and treatment modalities of intraocular melanoma, as well as the novel therapies currently being tested. DATA SOURCES: Clinically, it is important to determine which lesions carry a worse prognosis so as to offer patients the best treatment modalities available. Tumor location, size, histopathology, cytogenetic abnormalities, and tumor profiling are all used in determining the risk of death from metastatic disease of uveal melanocytic lesions. Despite successful local tumor control, up to 50% of patients have metastatic disease within 15 years of diagnosis; there is no effective treatment for metastatic disease.
CONCLUSIONS: Pathologists should be aware of the importance of tumor gross description, cellular histopathology classification, the use of fine-needle aspiration biopsy coupled with cytogenetics, and the new classification of uveal malignant melanomas that is based on chromosome 3 status.

Entities:  

Mesh:

Year:  2010        PMID: 21128775     DOI: 10.5858/2009-0441-RAR.1

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  14 in total

1.  Two cases of partial hepatectomy for malignant melanoma.

Authors:  Aaron I Karlen; Justin J Clark; Linda L Wong
Journal:  Hawaii J Med Public Health       Date:  2012-04

2.  Cepharanthine exerts antitumor activity on choroidal melanoma by reactive oxygen species production and c-Jun N-terminal kinase activation.

Authors:  Qi Zhu; Baofeng Guo; Linlin Chen; Qiuye Ji; Hang Liang; Naiyan Wen; Ling Zhang
Journal:  Oncol Lett       Date:  2017-03-29       Impact factor: 2.967

3.  Melanoma as a subsequent neoplasm in adult survivors of childhood cancer: a report from the childhood cancer survivor study.

Authors:  A S Pappo; G T Armstrong; W Liu; D K Srivastava; A McDonald; W M Leisenring; S Hammond; M Stovall; J P Neglia; L L Robison
Journal:  Pediatr Blood Cancer       Date:  2012-08-08       Impact factor: 3.167

4.  An Infrared Dye-Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma.

Authors:  Rhonda C Kines; Isabella Varsavsky; Sanghamitra Choudhary; Debaditya Bhattacharya; Sean Spring; Roger McLaughlin; Shin J Kang; Hans E Grossniklaus; Demetrios Vavvas; Stephen Monks; John R MacDougall; Elisabet de Los Pinos; John T Schiller
Journal:  Mol Cancer Ther       Date:  2017-12-14       Impact factor: 6.261

5.  Uveal melanoma.

Authors:  Vasilios P Papastefanou; Victoria M L Cohen
Journal:  J Skin Cancer       Date:  2011-06-30

6.  Molecular bases of cutaneous and uveal melanomas.

Authors:  Sudeep Gaudi; Jane L Messina
Journal:  Patholog Res Int       Date:  2011-08-18

Review 7.  Eye Globe Abnormalities on MR and CT in Adults: An Anatomical Approach.

Authors:  James Thomas Patrick Decourcy Hallinan; Premilla Pillay; Lilian Hui Li Koh; Kong Yong Goh; Wai-Yung Yu
Journal:  Korean J Radiol       Date:  2016-08-23       Impact factor: 3.500

8.  ZEB1 Regulates Multiple Oncogenic Components Involved in Uveal Melanoma Progression.

Authors:  Yao Chen; Xiaoqin Lu; Diego E Montoya-Durango; Yu-Hua Liu; Kevin C Dean; Douglas S Darling; Henry J Kaplan; Douglas C Dean; Ling Gao; Yongqing Liu
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

9.  Rare Occurrence of an Intraocular Choroidal Solitary Fibrous Tumor/Hemangiopericytoma.

Authors:  Lorenzo Rinaldo; Sarah Chao Ying Xu; Scott D Eggers; Diva R Salomão; John J Chen; Aditya Raghunathan
Journal:  Ocul Oncol Pathol       Date:  2017-12-16

10.  Ocular melanoma metastasizing to intra-abdominal lymph nodes.

Authors:  David Aranovich; Karen Meir; Michal M Lotem; Liat Appelbaum; Hadar Merhav
Journal:  Case Rep Surg       Date:  2013-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.